Interstitial lung diseases (ILD) significantly impact patient morbidity and mortality. As an ILD Center of Excellence, the Temple Lung Center has established comprehensive programs for the evaluation and management of patients with a wide range of ILDs. This includes extensive clinical research and lung transplantation expertise.

Temple Lung Center is a leading center for the evaluation and transplantation of patients with scleroderma and other disorders that contribute to esophageal dysfunction requiring lung transplantation. Temple has vast experience in performing transplants for patients with various ILDs, including those related to connective tissue diseases. Our physician-researchers are at the forefront of cutting-edge drug development, with several innovative clinical trials currently underway. These trials include those focusing on targeted therapies delivered via inhaled, oral, or subcutaneous routes for patients with ILDs such as idiopathic pulmonary fibrosis, scleroderma-related ILD, and progressive pulmonary fibrosis secondary to any causes, including non-scleroderma connective tissue diseases.

The chart below highlights clinical trials that are either actively enrolling or will soon be open for patients with these disorders, along with a triage map to help identify the most appropriate study for each patient. Patients can be evaluated at any of our clinical sites, and additional locations can be found at clinicaltrials.gov.

For more details about clinical research trials at the Temple Lung Center, email breathebetter@tuhs.temple.edu or call 215-707-1359.